http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Petsuksiri, Janjira (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Advanced Imaging Applications for Locally Advanced Cervical Cancer
Petsuksiri, Janjira,Jaishuen, Atthapon,Pattaranutaporn, Pittayapoom,Chansilpa, Yaowalak Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.5
Advanced imaging approaches (computed tomography, CT; magnetic resonance imaging, MRI; $^{18}F$-fluorodeoxyglucose positron emission tomography, FDG PET) have increased roles in cervical cancer staging and management. The recent FIGO (International Federation of Gynecology and Obstetrics) recommendations encouraged applications to assess the clinical extension of tumors rather than relying on clinical examinations and traditional non-cross sectional investigations. MRI appears to be better than CT for primary tumors and adjacent soft tissue involvement in the pelvis. FDG-PET/CT has increased in usage with a particular benefit for whole body evaluation of tumor metabolic activity. The potential benefits of advanced imaging are assisting selection of treatment based upon actual disease extent, to adequately treat a tumor with minimal normal tissue complications, and to predict the treatment outcomes. Furthermore, sophisticated external radiation treatment and brachytherapy absolutely require advanced imaging for target localization and radiation dose calculation.
-
Setakornnukul, Jiraporn,Petsuksiri, Janjira,Wanglikitkoon, Sirentra,Warnnissorn, Malee,Thephamongkhol, Kullathorn,Chansilp, Yaowalak,Veerasarn, Vutisiri Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.5
Background: To evaluate treatment outcomes of patients with stage I-III endometrial cancer treated with postoperative radiation. Materials and Methods: A retrospective review of 166 endometrial cancer patients, undergoing surgery and postoperative radiotherapy at Siriraj Hospital from 2005-2008 was performed. Pathology was reviewed. Results of treatment were reported with 5-year loco-regional recurrence free survival (LRRFS), 5-year overall survival (OS), patterns of failure and toxicity, and according to stage and risk groups. Results: Median follow up time was 62.8 months. Pathological changes were found in 36.3% of the patients after central reviews, leading to 19% changes in risk groups. Most of the patients (83.7%) received pelvic radiation (PRT) and vaginal brachytherapy (VBT). Five-year LRRFS and OS of all patients were 94.9% and 85.5%, respectively. There was no recurrence or death in low and low-intermediate risk groups. For the high-intermediate risk group, 5-year LRRFS and OS were 96.2% and 90.8%, respectively, and for the high risk group 90.5% and 71%. Late grade 3 and 5 gastrointestinal toxicity was found in 3% and 1.2% of patients, respectively. All of them received PRT 5,000 cGy in 25 fractions. Conclusions: Low and intermediate risk patients had good results with surgery and adjuvant radiation therapy. For high risk patients, postoperative radiation therapy alone appeared to be inadequate as the most common pattern of failure was distant metastasis.
-
Sompop Kuljarusnont,Janjira Petsuksiri,Pattama Chaopotong,Vuthinun Achariyapota,Pisutt Srichaikul,Atthapon Jaishuen 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.5
Objective: To evaluate the recurrence rates and patterns of failure in patients with stage Iendometrial carcinoma after surgical staging without adjuvant therapy. Methods: Medical records of 229 patients with stage I endometrial carcinoma, treated withsurgery alone between 2002 and 2010 at Siriraj Hospital were retrospectively reviewed. Theprimary objective of this study was recurrence rates. The secondary objectives were patternsof failure, disease-free survival, overall survival, and prognostic factors related to outcomes. Results: During median follow-up time of 53.3 months, 11 recurrences (4.8%) occurred witha median time to recurrence of 21.2 months (range, 7.7 to 77.8 months). Vaginal recurrencewas the most common pattern of failure (8/11 patients, 72.7%). Other recurrences werepelvic, abdominal and multiple metastases. Factors that appeared to be prognostic factors onunivariate analyses were age and having high intermediate risk (HIR) (Gynecologic OncologyGroup [GOG] 99 criteria), none of which showed significance in multivariate analysis. Therecurrence rates were higher in the patients with HIR criteria (22.2% vs. 4.1%, p=0.013) orpatients with stage IB, grade 2 endometrioid carcinoma (9.4% vs. 4.3%, p=0.199). Five-yeardisease-free survival and 5-year overall survival were 93.9% (95% CI, 89.9 to 5.86) and 99.5%(95% CI, 97.0 to 99.9), respectively. Conclusion: The patients with low risk stage I endometrial carcinoma had excellentoutcomes with surgery alone. Our study showed that no single factor was demonstrated to bean independent predictor for recurrence.
-
Jaishuen, Atthapon,Kunakornporamat, Kate,Viriyapak, Boonlert,Benjapibal, Mongkol,Chaopotong, Pattama,Petsuksiri, Janjira,Therasakvichya, Suwanit Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.6
Background: To study the incidence of non-endometrioid carcinoma of endometrium and compare the clinical characteristics and treatment outcomes with endometrioid carcinoma patients. Materials and Methods: This study included 236 patients with endometrial carcinoma at Siriraj Hospital whom were diagnosed and treated from 2003 through 2006. The clinical characteristics, pathological features, treatment and clinical outcomes were collected from the medical records. The 5-year survival was calculated according to 2009 FIGO staging. Results: Non-endometrioid carcinoma of endometrium accounted for 10.2% of all endometrial carcinomas (24/236 patients). The 5-year survival rate was significantly lower in the non-endometrioid group compared to the endometrioid group (77.3% vs 96%, p<0.001) and clinical data pointed to greater malignancy. Conclusions: Non-endometrioid carcinoma of endometrium is relative rare but is more aggressive, has more distant metastasis at diagnosis with a worse survival rate than endometrioid carcinoma. Only patients in stage IA with no residual disease on a hysterectomy specimen may not need adjuvant treatment.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
